Myeloproliferative Neoplasms News

HemOnc Today and Healio.com/HemOnc will provide live coverage of the Chemotherapy Foundation Symposium, which will be held Nov. 8-10 in New York.

The FDA lifted the clinical hold on phase 1 trials designed to evaluate UCART123 for the treatment of acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm, according to the drug’s manufacturer.

Nearly 2 years after former Vice President Joe Biden unveiled the cancer moonshot initiative, The Lancet Oncology Commission has detailed a roadmap to deliver on the recommendations of the moonshot’s blue ribbon panel.

ASH today announced the election of three new members to its executive committee.

Despite early advances, immunotherapy with PD-1 and PD-L1 inhibitors faces an unknown future for the treatment of hematologic malignancies.

The FDA approved IV rolapitant in combination with other antiemetic agents to prevent delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy for adults.

Oncology leaders who participated in an American Association for Cancer Research webinar this afternoon highlighted several advances in cancer research and emphasized the importance of robust medical research funding.

NIH launched the Partnership for Accelerating Cancer Therapies, a 5-year public-private research collaboration.

HemOnc Today is pleased to announce plans for a 3-day CME meeting designed to offer expert perspectives and practical insights into the use of immunotherapy and targeted treatments in cancer care.

A deficiency in vitamin D prior to allogeneic hematopoietic stem cell transplantation increased risk for relapse among patients with myeloid malignancies, according to a retrospective study published in Journal of Clinical Oncology.